cyrilzakka/clinical-trials huggingface dataset:
Influencing Factors of Coronary Heart Disease in Young People

The incidence of coronary heart disease in young people is not uncommon and the investigators will explore the factors contributing to this outcome

Through the multi-center clinical research conducted by several units in Nantong city, the risk factors and aggregation of the incidence of CHD among young people in nantong city were obtained, so as to fill in the blank of domestic multi-center research and reduce the incidence of CHD among young people.The investigators will conduct a long-term follow-up study on the young patients with CHD to screen the factors contributing to the poor prognosis of CHD in young patients.The investigators will fill this gap and intervene early to improve patients' quality of life and prolong their survival

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed coronary heart disease
* Confirmed by coronary angiography
* Diagnosed myocardial infarction
* Willing to sign an inform consent

Exclusion Criteria:

* Patients won't sign an inform consent or will not comply with the follow up.
A Study Designed to Evaluate Tear Production

The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).

Qualified subjects will attend a single visit.

This is a Phase 3b. 2 stage study. In Phase 1, approximately 40 subjects will be enrolled, after which the study will be paused and an analysis will be conducted. Results from the Stage 1 analysis will help inform the design of Stage 2. An additional 40 subjects are planned for Stage 2.

For both stages, the primary endpoint and analysis will remain the same. Stage 2 will be tested independently with no pooling of data between stages.

Eligibility Criteria:
Key Inclusion Criteria:

* Within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported.
* Within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms.
* Have a corrected visual acuity score of 20/200 or better in both eyes.
* Have good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history.
* Other protocol specified inclusion criteria may apply.

Key Exclusion Criteria:

* Current evidence of any clinically significant ophthalmic disease other than dry eye (for example, glaucoma or macular degeneration).
* History of ocular surgery within 1 year of the Study Visit.
* Use of contact lenses in either eye within 7 days of the Study Visit.
* Use of lid hygiene (all forms of lid care) or heat masks within 7 days of the Study Visit.
* Use of any topical ocular anti-inflammatory medications, any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 30 days of the Study Visit.
* Other protocol-specified exclusion criteria may apply.
tDCS to Treat Hemiplegic Shoulder Pain

The purpose of the study is to investigate the possibility of treating Hemiplegic Shoulder Pain (HSP) using transcranial direct current stimulation (tDCS) in patients following stroke.

The secondary aims are to see if this treatment affects motor function of the upper limb, to asses the different types of HSP and whether there is any correlation to the location and extent of the stroke.

Hemiplegic Shoulder Pain (HSP) is a common entity following stroke. It's prevalence varies between studies, probably because it includes many etiologies and there is no one way of diagnosis.

HSP delays rehabilitation, elongates hospitalization time and reduces quality of life.

Currently there is no one reccomended treatment for HSP. Weak transcranial direct current stimulation (tDCS) induces persisting excitability changes in the human motor cortex. this effect depends on the stimulation polarity and is specific to the site of stimulation. Interacting with cortical activity, by means of cortical stimulation, can improve the rehabilitation potential of neurologic patients. In this respect, preliminary evidence suggests that cortical stimulation may play a role in treating aphasia, unilateral neglect, and chronic pain disorders.

In this tDCS study the investigator uses one anode and one cathode electrode placed over the scalp to modulate a particular area of the central nervous system (CNS). The stimulation is administered via the neuroConn DC.Stimulator. The DC-STIMULATOR is a micro-processor-controlled constant current source. The DCSTIMULATOR is a CE-certified medical device for conducting non-invasive transcranial direct current stimulation (tDCS) on people.Electrode positioning is determined according to the International EEG 10-20 System.

Eligibility Criteria:
Inclusion Criteria:

* Patients hospitalized in the department of neurologic rehabilitation of Loewenstein Rehabilitation Center after first clinical stroke.
* Able to understand and comply with basic instructions
* Signed an informed consent form
* Hebrew speaking

Exclusion Criteria:

* Shoulder pain predating the stroke
* Epilepsy
Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain

The purpose of this study is to determine whether a new medical technology can help reduce post-operative pain. The new technology is called Transcranial Direct Current Stimulation.

This study aims to evaluate the effectiveness of transcranial direct current stimulation (tDCS) in the management of postoperative pain. Specifically, this study will determine whether patients undergoing any type of inpatient surgical procedure that routinely requires at least a 1-day inpatient stay post-operatively will report less pain and use less opioid analgesics following a series of 20-minute sessions of tDCS (compared to sham tDCS) delivered up to twice per day post-operatively. In addition to comparing the effects of real tDCS to sham tDCS, the present study will evaluate the interaction of dose (number and frequency of tDCS sessions) and surgery type.

Eligibility Criteria:
Inclusion Criteria:

* 18 years-75 years of age
* surgery at Medical University of South Carolina
* at least 2 days of post-operative stay

Exclusion Criteria:

* history of seizures or epilepsy
* family history of seizures
* taking any medications shown to lower seizure threshold
* metal implants above the waist
* pregnant
* brain tumors or lesions
* pacemaker
Use of Benzodiazepines and Z Drugs in the Elderly

The aim of this study is to evaluate benzodiazepines and related drugs (zolpidem and zopiclone) usage in an outpatient population of chronic users over 65 years in France using a questionnaire assessing substance dependence according to DSM-IV (Diagnostic and Statistical Manual of mental disorders) international standards.

1100 patients will be recruited by pharmacists. They will answer to a standardized questionnaire assessing their benzodiazepines or related drugs usage (phone contact).

Pharmacists are recruited by all French Centers For Evaluation and Information on Pharmacodependence (CEIP).

Eligibility Criteria:
Inclusion Criteria:

* 65 years old or more,
* benzodiazepines or benzodiazepines related drugs treatment for at least three months,
* written consent and without exclusion criteria.

Exclusion Criteria:

* no written consent form
* difficulties to understand or speak french
Iluvien Registry Safety Study

The study will include any patient treated with Iluvien at designated sites in European countries where marketing authorization has been granted in order to obtain broader safety and usage information.


Eligibility Criteria:
Inclusion Criteria:

* Any patient treated with Iluvien under this protocol will be included in the study.

Exclusion Criteria:

* Patients/Guardians who are unable to understand and sign the Informed Consent will be excluded from the study.

Retrospective Enrollment Criteria

Patients treated with ILUVIEN prior to study initiation may be included provided they satisfy the inclusion and exclusion criteria, where applicable, as well as, the following requirements:

1. The site is allowed to enroll a patient who was treated with ILUVIEN no more than 36 months prior to bringing the patient in for their first study visit.
2. The eligible patient must meet the data requirements as specified in the protocol, i.e., baseline data collected within 7 days prior to treatment with ILUVIEN and additional data subsequently collected approximately every 6 months thereafter until enrolment into the study.
3. The eligible patient must be enrolled at least one year prior to the planned end of the study.
Screening for Hepatitis C Using a Rapid Diagnostic Orientation Test (TROD) in Patients Over 50 Years Old in the Digestive Endoscopy Department of the Europeen Hospital Marseille

Chronic viral hepatitis C is a public health problem and several management recommendations are available. According to the French High Authority of Health, hepatitis C screening consists of a targeted screening of people at risk of infection by the virus, in particular drug users, people from countries with a high prevalence of the virus or who have received care in those countries, people transfused before 1992, or people who are or have beenincarcerated .

French government recommendations aim to achieve elimination of hepatitis C virus HCV (as early as 2025) and since April 2018 the European Hospital Marseille is engaged in this battle and organizes every year "the day without hepatitis" in the hospital.

Since 2017, direct-acting antiviral treatments have become available in France to all patients infected with HCV, regardless of the degree of severity of their disease. These treatments are effective in more than 95% of cases and, in 2019, 18,000 people were cured. As of today, it is estimated that there are still 110,000 people likely to be treated in France. Among them, 75,000 are unaware of being HCV positive, people who need to be tested.

With one of the largest volumes of digestive endoscopic examinations in France, the European Hospital Marseille may be a significant source of screening for hepatitis C.

Our study proposes to evaluate hepatitis C screening in consenting patients hospitalized in the endoscopy department at the European Hospital Marseille.


Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 50
* Giving free and informed written consent
* Being affiliated with or benefiting from a social security scheme

Exclusion Criteria:

- Patient unable to express consent
[11C]Yohimbine PET Study of alpha2-AR

The main purpose of this study is to model tissue specific kinetics of \[11C\]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of \[11C\]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).


Eligibility Criteria:
Inclusion Criteria:

* Healthy male volunteers
* Age between 20 years and 35 years
* Weight between 50kg and 90kg
* Without neurologic or psychiatric history
* Without head trauma history including loss of consciousness superior to 30 minutes.
* Affiliated to a social security or similar scheme
* Not subject to any legal protection measures
* Participant must have signed an informed consent document indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study and comply with the study procedures and restrictions

Exclusion Criteria:

* Allen test (assessing the arterial blood flow to the hand) indicating abnormal blood supply to the hand
* Subject with orthostatic hypotension
* Subject with alcohol or substance abuses history
* Subject with somatic drug therapies
* MRI contraindications (implanted or embedded metal objects in the head or body)
* PET contraindications
* Clonidine contraindications
* Exposed to 1 millisievert or more of ionizing radiation in the year before the start of this study
* Subject unable to sign written consent for participation in the study
Measurement of Midazolam Levels in Follicular Fluid

To determine the impact of Midazolam levels in follicular fluid on morpho-kinetics and morpho-genetics.

The reason to measure Midazolam levels in larger size follicles in this study is to maximize the chances to get a mature oocyte and therefore develop into a potential embryo to be analyzed.

The correlation of Midazolam levels in follicular fluid and euploid status of the embryos is worth exploring as no data exists that suggests any influence on the quality of the embryos from using this substance for IVF since its earliest days. Measuring time lapsed from injection to first oocyte retrieval as well as time lapsed in between first and last oocyte retrieved will grand insight into the rise of levels of Midazolam inside the follicular fluid, correlated with the chromosomal status and the morphokinetic development of the euploid embryos.

Eligibility Criteria:
Inclusion Criteria:

* Infertility (prim. / sec.)
* Age \>18 - ≤ 38 years.
* BMI 19-30
* Stimulation in GnRH-antagonist protocol, using rFSH
* Expected normal ovarian response (6)
* At least 4 follicles with the size ≥ than 17 mm on the day of OPU
* Patients undergoing PGS
* Able to understand the aim of the study and to provide consent

Exclusion Criteria:

* History of endometriosis, classified according to the American Fertility Society (AFS) as stage 3 or more.
* Severe male factor
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

A study to assess the real-life management and use of healthcare resources during the initiation of:

* Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
* Venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del\[17p\]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.


Eligibility Criteria:
Inclusion Criteria:

* Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study.
* Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy.

Exclusion Criteria:

* Currently participating in an interventional study.
* Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL.
Efficacy of Fibrin Sealant in Hypospadias Surgery

The aim of the study was to evaluate if application of a fibrin sealant over the urethroplasty suture line for waterproofing instead of a dartos vascularized pedicled flap to reduce complications and improve the outcome in hypospadias repair.

Many procedures have been tried for the sake of proper management of hypospadias and reducing the complications. Of them, tabularized incised plate (TIP) is one of the most convenient technique, which became the most common procedure for hypospadias repair (Elsayem et al., 2022).

Although many surgical modifications and techniques have been prescribed to minimize post-operative complications and improve outcomes, a high percentage of complications still occurs. Urethrocutaneous fistulae are the most common post-operative complication (10%-40%) after hypospadias surgery; other complications being skin flap related complications such as flap necrosis, suture line breakdown, ascent of the testis and penile torsion (Shenoy et al.,2021).

In this thesis a secondary preputial dartos flap will be performed in all cases and we will evaluate the value of usage of fibrin glue on the 1ry suture line .

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria All treatment naïve children with hypospadias.

Exclusion Criteria:

* Adult hypospadias.
* Recurrent cases.
* Prio pelvic trauma or radiation.
Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient

Sepsis is a serious health problem with a very high mortality in the ICU. The most important treatment for sepsis is the fastest possible antibiotic therapy. The identification of the pathogen responsible for sepsis is essential to propose an appropriate antibiotic treatment. However, the diagnosis of bacteremia by blood culture requires an average delay of 48 to 72 hours. The new test proposed by OCEAN Dx makes it possible to identify a bacteremia in a few hours. The main objective of the study is to evaluate the performance of the rapid identification test for bacteremia proposed by OCEAN Dx compared to a classic diagnostic strategy using blood cultures.

Sepsis is a worldwide problem. The World Health Organization estimates that around 49 million people suffer from sepsis each year. It is responsible for an unacceptable number of deaths, estimated at around 11 million. The severity of sepsis is not only related to the infection itself, but often to a too late diagnosis and an important heterogeneity in the management of patients. The identification of the pathogen responsible for sepsis is currently based on the positivity of bacteriological samples, particularly blood cultures. However, the diagnosis of bacteremia by blood cultures requires an average delay of 48 to 72 hours, which is not conducive to rapid adaptation of antibiotic therapy. The test proposed by OCEAN Dx offers the identification of a bacteremia in a few hours thanks to the recognition of the bacterial DNA in the patient's blood. The main objective of the study is to evaluate the performance of the rapid identification test for bacteremia offered by OCEAN Dx in comparison with a classical diagnostic strategy using blood cultures.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age admitted to an intensive care unit (ICU) with a suspected or documented infection requiring blood cultures.

Exclusion Criteria:

* Patient under 18 years of age
* Pregnant or breastfeeding woman
* Patient of legal age, under guardianship or deprived of liberty
* Not affiliated to a social security regime or not benefiting from such a regime.
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma

The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.

This study is for subjects that have been diagnosed with cancer in their arm, leg, or trunk (the part of the body that involves the chest, abdomen, and pelvis). The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body. This study will look at early side effects and effectiveness of preoperative 5-day Hypofractionated radiotherapy. Active participation in the study will take about 12 visits and are completed once the participant has a 6-month post-operation visit.

Eligibility Criteria:
Inclusion Criteria:

* Willingness and provision of informed consent via signed and dated copy.
* Histologically confirmed STS of extremity or trunk.
* Male or female, aged greater than or equal to 18 years old
* ECOG performance status 0-3
* Meets screening criteria for receipt of radiotherapy.
* Deemed eligible for wide local excision.
* Patient and/or physician identified possible barriers to receiving a 5-week course of conventionally fractionated preoperative radiotherapy. Potential barriers include but are not limited to concern for local progression that could precluded or complicate limb sparing surgery, concern for distant progression that could result in patient being non-operative, financial and/or physical burden of travel for daily treatments, financial burden of time away from work or caregiving.

Exclusion Criteria:

* Distant metastatic disease
* Prior radiation therapy in the proposed treatment area
* Simultaneous treatment of another malignancy
* Women who are pregnant or plan to become pregnant during the period of radiation therapy
* Planned concurrent administration of chemotherapy and radiation therapy
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3 doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with each dose given approximately 1 month apart.


Eligibility Criteria:
Inclusion Criteria:

* Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
* Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccination
* Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy
* No previous vaccination with a pneumococcal vaccine
* Subject or parent/legal guardian able to complete an electronic diary

Exclusion Criteria:

* Acquired immune deficiency syndrome (AIDS) at time of enrollment
* Current illicit substance and/or alcohol abuse
* History of active chronic viral hepatitis
* Previous anaphylactic reaction to a vaccine or vaccine-related component
* Serious chronic disorders including metastatic malignancy and end-stage renal disease
Endoscopic Resection for Small Rectal Neuroendocrine Tumors

In previous single center study, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) and mEMR-C was inferior to ESD for the treatment of small rectal NETs (≤10 mm), as it has shorter operation times and lower hospitalization costs. However, a multicenter randomized controlled trial is needed to prove the universality and generality of these findings.

Investigators aimed to conduct a muticenter randomized controlled trial to compare mEMR-C with ESD for the treatment of small rectal neuroendocrine tumors (NETs) in six tertiary hospitals in China.

Eligibility Criteria:
Inclusion Criteria:

1. Age from 18 to 75 years;
2. With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
3. With tumor size ≤10 mm assessed by colonoscopy;
4. Plan to receive mEMR-C or ESD treatment and provide written informed consent;

Exclusion Criteria:

1. Unable to tolerate ESD or MEMR-C as assessed by the research team of each center;
2. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
3. Rectal NET with lymph node metastasis or distant metastasis;
4. Received resection of rectal neuroendocrine tumor by other surgical procedures;
5. Multiple rectal neuroendocrine tumors;
6. Vulnerable groups such as pregnant women or patients with mental disorders;
7. Poor compliance, unable to cooperate with treatment.